-transparent.png){kind=logo}
Transplantation of human AML into severe combined immunodeficient (SCID) mice provides a useful experimental model but graft failures have been reported. We investigated the influence of a number of factors on the outgrowth of AML in the SCID mouse bone marrow (BM). The transplantation route and total body irradiation (TBI) were examined using the cell line HL-60 as a model for AML. The role of graft size and recombinant human IL-3 (IL-3) were investigated with patient samples of AML cells. Intravenous transplantation was demonstrated to be superior to intraperitoneal transplantation. Pretransplant conditioning resulted in a dose-dependent increase of AML growth in the SCID mouse. Cell dose titrations ranging from 3 x 10(7) - 3.6 x 10(5) AML cells i.v. per mouse revealed a minimum of 1.1 x 10(6) required for reproducible engraftment. Earlier and more extensive infiltration by human AML cells was seen following injection of greater cell numbers. IL-3 given post-transplantation SCID mouse recipients, promoted AML growth in three cases, whereas a fourth AML cell specimen also grew without support of IL-3. In vitro growth factor responsiveness of AML cells to IL-3 did not predict IL-3 dependence of AML growth in vivo.
W Terpstra, and
A Prins, and
T Visser, and
B Wognum, and
G Wagemaker, and
B Löwenberg, and
J Wielenga
September 1998,
Hematological oncology,
W Terpstra, and
A Prins, and
T Visser, and
B Wognum, and
G Wagemaker, and
B Löwenberg, and
J Wielenga
April 2003,
Leukemia,
W Terpstra, and
A Prins, and
T Visser, and
B Wognum, and
G Wagemaker, and
B Löwenberg, and
J Wielenga
September 2002,
Leukemia,
W Terpstra, and
A Prins, and
T Visser, and
B Wognum, and
G Wagemaker, and
B Löwenberg, and
J Wielenga
April 2008,
Experimental hematology,
W Terpstra, and
A Prins, and
T Visser, and
B Wognum, and
G Wagemaker, and
B Löwenberg, and
J Wielenga
October 2012,
Cancer biology & therapy,
W Terpstra, and
A Prins, and
T Visser, and
B Wognum, and
G Wagemaker, and
B Löwenberg, and
J Wielenga
January 2004,
Stem cells (Dayton, Ohio),
W Terpstra, and
A Prins, and
T Visser, and
B Wognum, and
G Wagemaker, and
B Löwenberg, and
J Wielenga
January 2010,
Leukemia research,
W Terpstra, and
A Prins, and
T Visser, and
B Wognum, and
G Wagemaker, and
B Löwenberg, and
J Wielenga
September 2014,
Journal of leukemia (Los Angeles, Calif.),
W Terpstra, and
A Prins, and
T Visser, and
B Wognum, and
G Wagemaker, and
B Löwenberg, and
J Wielenga
March 1999,
Praxis,
W Terpstra, and
A Prins, and
T Visser, and
B Wognum, and
G Wagemaker, and
B Löwenberg, and
J Wielenga
January 2019,
[Rinsho ketsueki] The Japanese journal of clinical hematology,
